Enclomiphene citrate stimulates testosterone production while preventing oligospermia A randomized phase II clinical trial comparing topical testosterone
Treatment with enclomiphene increases serum T, E2, and LH levels similar to those obtained with topical T gel in men with secondary hypogonadism with no lowering of sperm count.
Ronald D. Wiehle, Ph.D., Gregory Fontenot, Ph.D., Jenny Wike, B.S., Kuang Hsu, M.S., Jennifer Nydell, B.S. Larry Lipshultz, M.D.
Volume 102, Issue 3, Pages 720-727
To determine the effect of enclomiphene citrate in men with secondary hypogonadism.
Phase II clinical trial.
Community dwelling men making visits to physician offices.
Men with secondary hypogonadism.
Oral administration of enclomiphene citrate or 1% topical T gel.
Main Outcome Measure(s):
Luteinizing hormone, FSH, T, and semen analysis.
Treatment with enclomiphene citrate resulted in increased morning serum T, E2, and LH levels similar to those obtained with a topical T gel in men with secondary hypogonadism. Follicle-stimulating hormone and LH were increased with enclomiphene, and sperm counts were conserved.
Enclomiphene citrate reverses the two hallmarks of secondary hypogonadism, namely, low serum total T and low or inappropriately normal LH while preserving sperm production.
Clinical Trial Registration Number:
NCT01270841 (ClinicalTrials.gov Identifier NCT01270841).